<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04225884</url>
  </required_header>
  <id_info>
    <org_study_id>3129002</org_study_id>
    <nct_id>NCT04225884</nct_id>
  </id_info>
  <brief_title>Digital Therapeutics (DTx) for Pain: Pilot Study of a Virtual Reality Software for Chronic Pain</brief_title>
  <acronym>VIRPI</acronym>
  <official_title>DTx for Pain: Behavioural Revalidation in Augmented and Virtual Reality for Chronic Pain; and Exploratory Pilot Study of a Virtual Reality Software</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomised, double-blind, 3-arm parallel group comparison of 2 different virtual
      reality softwares and standard care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, randomised, double-blind, 3-arm parallel group comparison of DTx for pain
      (treatment A), control (treatment B) and an open standard care arm, over 6-8 weeks. An
      optional adaptive, multi-objective, multi-purpose, extension is included. Study devices will
      be delivered to the patient's home with instructions for use; patients will receive remote
      technical support.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Self-report of disability, Oswestry</measure>
    <time_frame>From randomisation upto 6-8 weeks</time_frame>
    <description>Oswestry Disability Index (subjects with a score of ≤22 will be considered as responders), index 0%-100% (0=no disability, 100=maximum disability possible).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Self-report of disability; Pain Interference</measure>
    <time_frame>From randomisation upto 6-8 weeks</time_frame>
    <description>The Patient Reported Outcomes Information System (PROMIS) 6b - Pain Interference Scale, score 6-30 (6=pain not at all interfering patient's life, 30=maximum interfering to patient's life).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective report of disability, steps</measure>
    <time_frame>From randomisation upto 6-8 weeks</time_frame>
    <description>Average number of steps per day over one week, as assessed by wearable equipment, 0-maximum amount of steps (0=patient not taking steps at all, maximum disability; maximum number of steps=minimum disability).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fear of movement and re-injury</measure>
    <time_frame>From randomisation upto 6-8 weeks</time_frame>
    <description>Tampa Scale of Kinesiophobia (TSK), score 17-68 (17=negligible or no kinesiophobia,68=extreme fear of pain with movement).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Behaviour, pain intensity</measure>
    <time_frame>From randomisation upto 6-8 weeks</time_frame>
    <description>Numerical Rating Scale, PROMIS 3a - Pain Intensity Scale, score 3-15 (3=no pain,15=very severe pain).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Behaviour, pain medications</measure>
    <time_frame>From randomisation upto 6-8 weeks</time_frame>
    <description>Any changes in pain medication during the study period are reported as outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life, own experience</measure>
    <time_frame>From randomisation upto 6-8 weeks</time_frame>
    <description>EuroQol-5D-5L-scale: European Quality (EQ) of Life (l), 5-dimension-5-level-scale. a). Descriptive System, 5-dimension-5-level-scale, scores are converted to a value where 1 equals 'perfect health' and 0 equals 'dead'. b). Visual Analogue Score, score 0 to 100 where 100 is the best health you can imagine and 0 = the worst health you can imagine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life, adverse events</measure>
    <time_frame>From randomisation upto 6-8 weeks</time_frame>
    <description>Adverse Event reporting, number of adverse events and their severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life, change</measure>
    <time_frame>From randomisation upto 6-8 weeks</time_frame>
    <description>Patient Clinical Global Impression of Change (PGIC) results, score 1-7 (1=very much improved, 7=very much worse).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Low Back Pain</condition>
  <arm_group>
    <arm_group_label>DTx for pain</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment A software</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Treatment B software</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Pain medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DTx for pain software</intervention_name>
    <description>Software with active intervention</description>
    <arm_group_label>DTx for pain</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control software</intervention_name>
    <description>Software without active intervention</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard care</intervention_name>
    <description>Pain medication</description>
    <arm_group_label>Standard care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Competent male or female adults (age ≥ 18 years).

          -  Chronic low back pain

          -  Written informed consent

          -  Finnish speaking

          -  having a clear, flat surface of at least 2 x 2 m of size to interact with DTx for pain

          -  Can stoop without severe pain

        Exclusion Criteria:

          -  History of epilepsy, migraine, vertigo or psychosis

          -  Confirmed diagnosis of cancer

          -  Prone to strong motion sickness requiring treatment

          -  Pregnancy

          -  Physiotherapy based interventions contraindicated

          -  Severe or acute structural pathologies (e.g. spondylitis, epidural abscess,
             spondylolisthesis, acute herniated or ruptured disc, traumatic injury, or severe
             spinal stenosis) that could be worsened by the intervention as assessed by the
             principal investigator

          -  Has received (in last 2 years) or is receiving formal psychotherapy from a
             psychologist for pain or allied health care professional at the screening stage

          -  Any other condition that would affect posture or balance, and

          -  Prior participation in DTx for pain feasibility study or in any part of the current
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Orion Pharma Clinical Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Orion Corporation, Orion Pharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Orion Pharma Clinical Study Director</last_name>
    <phone>+358 10 426 4184</phone>
    <email>clinicaltrials@orionpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CPU Orion Pharma</name>
      <address>
        <city>Espoo</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 20, 2019</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

